Camizestrant Patent Expiration
Camizestrant was first introduced by Astrazeneca Pharmaceuticals Lp
Camizestrant Patents
Given below is the list of patents protecting Camizestrant, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Etcamah | US12453729 | Pharmaceutical Formulations | Oct 22, 2041 | Astrazeneca |
| Etcamah | US12364689 | Dosage Regimen For The Treatment Of Cancer | Sep 18, 2041 | Astrazeneca |
| Etcamah | US10131663 | Chemical Compounds | Oct 13, 2037 | Astrazeneca |
| Etcamah | US10590130 | Chemical Compounds | Oct 13, 2037 | Astrazeneca |
| Etcamah | US10961241 | Chemical Compounds | Oct 13, 2037 | Astrazeneca |
| Etcamah | US12077530 | Chemical Compounds | Oct 13, 2037 | Astrazeneca |
Camizestrant's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List